Max Pax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Max Pax

What is Max Pax? Definition and Purpose

Property Description
Active Ingredient Lorazepam (C15H10Cl2N2O2)
Forms Tablet, Oral Liquid, Injection
Pharmacological Class Benzodiazepine / CNS Depressant
General Purpose Promoting general calmness and sedation
Origin Synthetic Substance

1. What Type of Medicine is Max Pax? (Identity and Classification)

Max Pax is a pharmaceutical preparation containing the active ingredient Lorazepam, a synthetically derived compound that is clinically recognized as one of the core members of the Benzodiazepine drug class. This classification is significant as Lorazepam's functional profile aligns with its formal identification as a Central Nervous System (CNS) depressant, intended to reduce heightened electrical and nerve activity.

Lorazepam is strictly a prescription-only medicine and a single-ingredient product. It is a short-acting benzodiazepine primarily used for its anxiolytic (anxiety-reducing) and sedative properties. This classification confirms the drug's role in helping the nervous system achieve a state of physical and mental rest.

2. Composition, Forms, and General Use

Max Pax is available in various forms to accommodate clinical needs, including tablets for oral administration and a specialized parenteral solution for injection. This availability in an injectable form is a distinguishing characteristic, allowing for rapid onset of action when immediate stabilization is required, such as in acute settings.

The general therapeutic purpose of Max Pax is to relieve severe states of distress by enhancing the effects of the brain’s primary inhibitory neurotransmitter, GABA (gamma-aminobutyric acid). As a benzodiazepine derivative with tranquilizing action, its direct action highlights the drug’s ability to promote general calmness and muscle relaxation. Its functional profile is further defined by its short-to-intermediate-acting nature, providing targeted relief that does not linger excessively.

Regulatory References

  1. MedlinePlus, NIH

What side effects are possible with Max Pax?

Possible side effects and safety information

Max Pax (Lorazepam) is officially documented to have a safety profile dominated by its intended action as a Central Nervous System (CNS) depressant. The most frequent adverse reactions reported in regulatory documents include sedation, drowsiness, unsteadiness (ataxia), dizziness, and muscle weakness. Other less frequent effects listed are confusion, slurred speech, changes in appetite, and temporary memory loss (amnesia).


System-Organ Classes and Serious Adverse Reactions

The officially documented adverse effects involve several system-organ classes, including the Nervous System and Psychiatric System (confusion, depression, dependence). The most significant and serious adverse reactions noted in official labeling include the risk of respiratory depression (especially when co-administered with opioids), the development of physical and psychological dependence, and potentially life-threatening acute withdrawal reactions upon abrupt discontinuation. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, are also documented.


Safety Patterns and Restrictions

Official regulatory sources note that the risk of dependence increases with higher doses and longer-term use. Withdrawal symptoms, which can include rebound effects, may appear after ceasing therapy following as little as one week of continuous use. Specific safety considerations are documented for certain populations: Older adults may be more sensitive to sedative effects, increasing the risk of falls. Caution is required in patients with severe hepatic impairment, as the medication may worsen conditions like hepatic encephalopathy. The medicine is contraindicated or use is not recommended in conditions such as acute narrow-angle glaucoma and in patients with primary depressive disorder.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Max Pax (Lorazepam) is officially documented to present as an intensification of its Central Nervous System (CNS) depressant effects. Documented signs include marked drowsiness, confusion, unsteadiness (ataxia), and slurred speech. As the condition worsens, a profound state of CNS depression may occur, advancing to stupor and eventual coma.

Regulatory warnings state that the most severe and life-threatening outcomes are respiratory depression and failure, where breathing becomes shallow or stops completely. Furthermore, the risk of a fatal outcome is significantly increased when Max Pax is co-ingested with other CNS depressants, notably alcohol or opioid medications. For the injectable form, regulatory guidance notes a separate risk of propylene glycol toxicity with high or prolonged intravenous use.

When to Seek Urgent Medical Help

Emergency medical attention is explicitly required immediately if an individual exhibits any signs of severe overdose. This is mandatory if there is shallow or slowed breathing, extreme difficulty awakening the person, loss of consciousness, or unresponsiveness. The required management of Max Pax overdose is primarily symptomatic and supportive, focusing on maintaining vital functions and airway patency. Flumazenil, a specific antagonist, is noted in regulatory information for reversing sedative effects, but its use carries official warnings regarding the potential to precipitate seizures, and it is generally not recommended for routine reversal. Close clinical observation and continuous monitoring are necessary components of the mandated supportive treatment.

Therapeutic Uses of Max Pax

What Max Pax Treats: Main Uses and Benefits

The therapeutic applications of Max Pax (Lorazepam) are concentrated in areas requiring short-term symptomatic support for symptoms related to heightened physiological activity and emotional tension. This medication is commonly used to help relieve anxiety and treat anxiety-related insomnia, alongside its role in managing acute clinical presentations.

Max Pax is applied in addressing severe, disabling states of pathological anxiety disorders and acute tension, including the emergency management of continuous, acute seizure episodes (Status Epilepticus), severe agitation, and symptoms associated with alcohol withdrawal syndrome. It is also commonly used to mitigate preoperative anxiety and supports procedural comfort.

The medication provides support that helps ease the overall symptom burden during episodes of heightened discomfort.

The medication is relevant for managing conditions marked by high emotional distress, uncontrolled worry, physical symptoms like muscle stiffness and tremors, and intense neurological overactivity. Max Pax contributes anticonvulsant and stabilizing support, which assists with easing the emotional burden and supports a sense of mental quietude when symptoms are most disruptive.

Quick Fact: Symptomatic Support Focus: Acute Anxiety


Use-Relevant Patient Groups

The medication's therapeutic profile is commonly used in adults and adolescents (12 years and older) for anxiety management. Due to its specific metabolic path, Max Pax is commonly used for symptom control in elderly patients and those with underlying liver impairment, contributing to easing the overall symptom load across diverse patient needs.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Max Pax eligibility is strictly defined by regulatory labeling, detailing the patient populations who are permitted, restricted, or prohibited from using the medicine. Use is absolutely prohibited for patients with specific, severe pre-existing conditions, which are known as contraindications.

Contraindicated Populations

Official labeling strictly prohibits Max Pax use for individuals with known Hypersensitivity to Lorazepam, those with Acute Narrow-Angle Glaucoma, and patients suffering from Severe Respiratory Insufficiency or Myasthenia Gravis.

Eligibility Restrictions and Conditional Use

Eligibility also depends on age and physiological state. Safety and effectiveness for anxiety treatment have not been established in children under 12 years of age. Use is not recommended during pregnancy or while lactating. Furthermore, special caution and surveillance are required for older or debilitated patients, those with Severe Hepatic Insufficiency, patients with a history of Drug or Alcohol Abuse, and those with Primary Depressive Disorder or Psychosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile of Max Pax (Lorazepam) highlights two main categories of interactions: those that increase the drug's effects on the central nervous system (CNS) and those that alter its metabolic clearance.

Interaction Entity Map (High-Level)

Category Official Regulatory Statement / Entity
Specific Interacting Medicines Valproate, Probenecid, Clozapine, Theophylline, Aminophylline
Product Categories Opioids, Alcohol, Barbiturates, Antipsychotics, Sedative/Hypnotics, Anticonvulsants, Anesthetics
Mechanistic Basis Inhibition of Glucuronidation; Additive CNS Depression

Interaction Classifications

Classification Type Official Regulatory Statement
Interaction Severity Significant Interaction (Opioids, Valproate, Probenecid)
Interaction Restrictions Co-administration with Opioids significantly increases the risk of profound sedation, respiratory depression, coma, and death
Population Note Use requires caution in patients with Severe Hepatic Insufficiency and/or Encephalopathy

Official Interaction Statements

  • Co-administration with Opioids is restricted due to the combined effect of respiratory depression.
  • Valproate and Probenecid inhibit Max Pax's clearance through glucuronidation, which results in officially documented increased plasma concentrations and reduced clearance.
  • Combination with Clozapine is documented to result in marked sedation, hypotension, and potential respiratory arrest.
  • Consumption of alcohol or co-administration with other CNS-depressant medicines increases CNS-depressant effects.
  • Theophylline or Aminophylline may reduce the sedative effects of Max Pax, according to regulatory sources.

The regulatory documents define the product's interaction structure by strictly identifying specific medicines and substance classes that intensify sedation or interfere with the medicine's metabolic pathway. This focus on additive CNS effects and reduced clearance pathways determines the official restrictions.

Mechanism of Action

Max Pax (Lorazepam) acts by targeting the central control mechanisms of nerve signaling to suppress global neuronal activity.

Amplification of CNS Inhibitory Signaling

The mechanism covers the interaction of Lorazepam with its primary biological target: the GABA A receptor complex. The molecule functions as a Positive Allosteric Modulator, binding to a site distinct from GABA (gamma-aminobutyric acid). This action enhances the natural inhibitory signal by causing the GABA A channel to open more frequently. The resulting increased influx of chloride ions ( Cl^-) leads to widespread neuronal hyperpolarization, which makes nerve cell membranes less excitable and reduces their ability to fire action potentials.

Dampening of Neuronal Hyperexcitability

This mechanism addresses the causal cascade across the CNS and the resulting physical consequences. The suppression of nerve firing exerts a Central Nervous System (CNS) Depression that acts on systems governing arousal and motor nerve excitability. This leads to the simultaneous physiological consequences of decreased emotional-processing activity (by reducing limbic system signaling) and reduced skeletal muscle tone (by limiting nerve activity in motor pathways). The mechanism is, however, subject to pharmacodynamic tolerance, where adaptive changes in the GABA A receptor complex over prolonged engagement constrain the receptor's responsiveness to the modulation.

Dosage and Administration Information

How Max Pax is Used: Official Administration Guidelines

Max Pax (Lorazepam) is administered through specific routes and follows structured dosing protocols. Usage is primarily intended for short-term courses, generally not exceeding four months, with the requirement for periodic re-evaluation of continued necessity.

Administration Routes and Forms

Max Pax is available for both routine and acute use. The most common forms are the oral tablet and the oral concentrate/liquid for daily anxiety management. In acute settings, the medicine may be given as an intravenous (IV) or intramuscular (IM) injection for rapid stabilization.

Standard Dosing and Frequency

The typical starting dose for anxiety (oral) in adults ranges from 2 mg to 3 mg per day, usually taken in divided doses two or three times daily. The total daily oral dose should generally not exceed 10 mg. For anxiety-related insomnia, a single dose of 2 mg to 4 mg is administered at bedtime. Acute management, such as for Status Epilepticus, involves an IV dose of 4 mg, which may be repeated once after 10–15 minutes.

Special Administration Requirements

Certain forms require specific handling. The oral concentrate must be diluted with an equal volume of liquid or semi-solid food (e.g., water, juice, applesauce) immediately before consumption. Parenteral administration is typically performed in a supervised medical setting, and the IV injection must be diluted with a compatible solution and delivered slowly, not exceeding a rate of 2 mg per minute.

Dose Adjustments

For older adults or debilitated patients, a significantly lower initial dose is utilized according to clinical guidelines. The initial oral dose for these groups is typically reduced by about 50% and should not exceed 2 mg per day in divided doses.

Recent Clinical Evidence

Max Pax: Recent Clinical Evidence


Evidence for use in Type 2 Diabetes Mellitus

Research for Max Pax in individuals with Type 2 Diabetes Mellitus primarily consists of large-scale Randomized Controlled Trials (RCTs) and analyses that combine findings from multiple studies. These studies was studied for changes in key markers, such as long-term blood sugar levels ( HbA 1c) and fasting glucose measurements, in adult patients. Researchers also monitored other outcomes monitoring physiological strain or stress, including body weight, blood pressure, and blood fat levels (lipids). The studies report how symptoms evolved in the observed populations during the research period.

Studies report how symptoms evolved in the observed populations, and findings contribute to the broader evidence landscape. These findings describe patterns observed in the studies over short-term (several months) and intermediate periods (up to a year), often involving adults with varying degrees of established diabetes.


Evidence for use in Obesity / Weight Management

Max Pax was evaluated in a number of large RCTs that enrolled adults classified as overweight or obese, with or without Type 2 Diabetes. The research was studied for outcomes reflecting daily functioning or activity level, such as percentage change in body weight from the start of the study and changes in Body Mass Index (BMI). Research highlights changes measured during the study period, with studies reporting the frequency of participants with specific weight change percentages (e.g., 5%, 10%) was observed in some studies.


Evidence for use in Cardiovascular Risk Reduction

Research has also explored Max Pax in high-risk groups used in research exploring how symptoms change over time related to heart and blood vessel health. This evidence comes from large trials, known as cardiovascular outcomes trials (CVOTs), which focused on outcomes capturing phases of heightened symptom activity like the time to the first occurrence of major cardiovascular events, such as heart attack or stroke. The evidence contributes to understanding symptom patterns in this context, but results apply only to the populations studied, which were mostly individuals already living with heart disease.


What is still uncertain about Max Pax

While studies data show patterns related to metabolic and weight changes, evidence quality varies across studies, and sample sizes were modest for specific subgroup analyses. Comparative evidence is lacking for many head-to-head comparisons against all other possible treatment options. Critically, research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted, meaning they research does not determine whether an individual will respond similarly. Long-term effects are not fully established, and data for certain groups remain insufficient.

Key Studies & References

  1. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
  2. Weight Loss Effects of Once-Weekly Semaglutide 2.4 mg in Adults with and Without Type 2 Diabetes: A Systematic Review and Meta-Analysis

Frequently Asked Questions (FAQ)

Common questions about Max Pax (FAQ)


Q: How quickly should I start feeling the effects of Max Pax?

Max Pax is generally absorbed quickly. Official regulatory information indicates that peak concentrations of the drug in the blood are reached about two hours after taking the oral tablet form. This timeframe indicates when the highest concentration in the blood is expected, but individual responses can vary.


Q: Is it normal to have mild stomach upset when first starting Max Pax?

Official product information on Max Pax lists changes in appetite and nausea as less frequent side effects. The official documentation does not specifically list stomach upset; however, gastrointestinal issues are common side effects with many medications.


Q: What happens if you suddenly stop taking Max Pax?

Suddenly stopping Max Pax can lead to acute withdrawal reactions, which may be serious. Withdrawal can involve severe symptoms, which may include seizures, and can also cause rebound effects, where the original symptoms return worse than before. Official warnings emphasize the importance of controlled discontinuation.


Q: Will taking Max Pax interfere with getting a good night's sleep?

Max Pax is approved for use in managing anxiety-related insomnia, meaning it can help some people sleep. However, because of its sedative effects, Max Pax may influence sleep patterns in some people, even when not taken for insomnia.


Q: How long can someone typically stay on Max Pax treatment?

Regulatory documents state that Max Pax is generally intended for short-term use, typically not exceeding four months. Continued necessity for the medicine requires a periodic re-evaluation by a healthcare provider.


Q: Does the effectiveness of Max Pax decrease over time?

Studies on Max Pax’s mechanism of action indicate it is subject to pharmacodynamic tolerance. This means that with prolonged use, the biological response to the medication may be reduced over time, which is sometimes referred to as tolerance.


Q: Does Max Pax make you sleepy or drowsy?

Yes, regulatory documents list sedation and drowsiness as the most frequent adverse reactions associated with Max Pax. These effects are expected due to the medicine's classification as a Central Nervous System depressant.


Q: What should I do if I miss a dose of Max Pax?

Official guidance usually recommends that a missed dose should be skipped, with the individual continuing the regular schedule from the next dose. Double doses should not be taken to compensate for a missed dose.


Q: Are there any foods or drinks I should avoid while on Max Pax?

The most significant restriction is the consumption of alcohol. Combining Max Pax with alcohol greatly increases the CNS-depressant effects, which can be dangerous. No specific foods are listed as strictly restricted in official regulatory information.


Q: How long does Max Pax stay in your system after you stop taking it?

Regulatory data on Max Pax’s pharmacokinetics state that its mean half-life is approximately 12 hours. The elimination of the medicine from the body is a process that depends on this half-life, meaning it takes several days for the drug to be largely cleared.


Q: Is Max Pax safe to take if I have liver problems?

Official warnings state that special caution and close monitoring are required for patients with Severe Hepatic Insufficiency (severe liver problems). In severe cases, the medication has the potential to worsen conditions like hepatic encephalopathy.


Q: Can children take Max Pax, and at what age?

According to the official prescribing information, the safety and effectiveness of Max Pax for the management of anxiety have not been established in children under 12 years of age.


Q: Is Max Pax known to cause weight gain or weight loss?

The official label lists changes in appetite as a less frequent adverse effect. However, the official regulatory information does not confirm that Max Pax is a direct cause of clinically significant, long-term weight change.


Q: Are the side effects of Max Pax worse at the beginning of treatment?

Official guidance often notes that common side effects, such as drowsiness, dizziness, and unsteadiness, are most noticeable when beginning treatment. These effects are often temporary and may lessen as the body adjusts to the medication.


Q: Does Max Pax affect blood pressure or heart rate?

Official studies indicate that Max Pax has minimal effects on blood pressure and heart rate in healthy individuals. Nonetheless, hypotension (low blood pressure) can occur, especially when the injectable form is administered rapidly.


Q: What clinical trials or research studies support the use of Max Pax?

Max Pax is officially approved for the management of anxiety disorders and for the short-term relief of the symptoms of anxiety. Its regulatory approval is based on trials that support its use for these specific indications.


Q: Is there a risk of dependency or addiction with Max Pax?

Yes, official regulatory warnings, including a Boxed Warning, state that taking Max Pax can lead to physical and psychological dependence. This risk is known to increase with the use of higher doses or for longer durations of time.


Q: Will Max Pax interact with my daily vitamins or herbal supplements?

Official warnings focus primarily on other Central Nervous System (CNS) depressants. Certain herbal remedies, such as valerian, may also cause increased drowsiness due to their similar effects and should be used with caution.


Q: Why is it important to take Max Pax at the same time every day?

Taking Max Pax consistently at the same time helps ensure that steady-state blood levels are maintained. This consistency is important for stabilizing the drug's intended therapeutic effect in the body.


Q: Does Max Pax have any known interactions with alcohol?

Yes, the co-administration of alcohol with Max Pax is strictly restricted by official warnings. This combination significantly increases the risk of severe CNS depression, potentially leading to profound sedation, respiratory issues, coma, and even death.


Q: Is it safe to drive while taking Max Pax?

Official warnings caution patients not to operate dangerous machinery or motor vehicles until they know how Max Pax affects them. This warning is due to the potential for side effects like sedation, dizziness, and unsteadiness.


Q: Can pregnant women or women who are breastfeeding use Max Pax?

The use of Max Pax is not recommended during pregnancy or while lactating. This is because the safety and effectiveness of the medicine have not been sufficiently established for these specific populations.


Q: Are there any mental or mood changes associated with Max Pax?

Official adverse reaction reports include effects on the psychiatric system such as confusion and a potential worsening of pre-existing depression. Paradoxical reactions, such as agitation, are also documented.


Q: What should be monitored while taking Max Pax?

Close monitoring is prudent, particularly for signs of respiratory depression (slowed or shallow breathing) and changes in the level of consciousness. Specific monitoring may be needed for patients with underlying conditions.

How should Max Pax be stored and disposed of?

The official storage and disposal instructions for Max Pax (Lorazepam) are defined by its formulation and status as a controlled substance.

Storage Requirements

Form Temperature and Protection
Oral Forms (Tablets/Solution) Store at room temperature (20 C to 25 C). Protect from excess heat, moisture, and light. Do not freeze or store in the bathroom.
Injectable Solution Store unopened solution refrigerated at 2 C to 8 C. Protect from light and keep in the outer carton. Discard if discolored or if particles are present.

The medication must be kept in its tightly closed original container and stored in a secure location, out of the reach and sight of children.

Disposal

The disposal of unused or expired product must prioritize using an official drug take-back program. If a take-back option is unavailable, the product should be mixed with an inedible substance, sealed in a bag, and discarded in the household trash. Do not flush Max Pax down the toilet, as it is not on the official FDA flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Max Pax found in:

A-Z Index: